Amyloidosis News - 2022

The US Food and Drug Administration (FDA) approved vutrisiran (AMVUTTRA™), an RNA interface therapeutic administered via subcutaneous injection once every 3 months, for adult patients with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis. Read More ›

A new study reports high antibody response rates after COVID-19 vaccination among patients with monoclonal gammopathies of unknown significance, smoldering myeloma, multiple myeloma, or light chain amyloidosis. Read More ›

Researchers from the United Kingdom analyzed the healthcare resources associated with diagnosis of transthyretin amyloidosis cardiomyopathy and estimated the time and cost-savings of an optimized diagnostic pathway. Read More ›

A guide describes how to use radiotracer scintigraphy for the accurate diagnosis of transthyretin amyloid cardiomyopathy. Read More ›

According to a global registry study, late-onset inherited transthyretin amyloidosis was more likely to be misdiagnosed and to present with more heterogeneous and severe symptoms compared with early-onset disease. Read More ›

Results of a recent study suggest that patients with cardiac amyloidosis are less likely to respond to cardiac resynchronization therapy than patients with dilated cardiomyopathy. Read More ›

Ixazomib plus dexamethasone may not improve response rate compared with physician’s choice of care but may delay organ deterioration and mortality in relapsed/refractory light chain amyloidosis. Read More ›

A study examined the hematologic and organ response rates to daratumumab in patients with relapsed/refractory light chain amyloidosis. Read More ›

As with the ventricles, amyloid infiltration in the atria may affect the severity of transthyretin amyloid cardiomyopathy. Read More ›

Cardiologists describe red flags that should raise suspicion of cardiac amyloidosis and provide a guide to noninvasive diagnostic techniques as alternatives to cardiac biopsy. Read More ›

Page 2 of 4

Amyloidosis News
Subscribe to Amyloidosis News

Stay up to date with Amyloidosis News by subscribing to receive the free AMN e‑Newsletter.